<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1248283</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2023.1248283</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Chlorin e6-modified iron oxide nanoparticles for photothermal-photodynamic ablation of glioblastoma cells</article-title>
<alt-title alt-title-type="left-running-head">Yao and Zhou</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fbioe.2023.1248283">10.3389/fbioe.2023.1248283</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yao</surname>
<given-names>Hongqing</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhou</surname>
<given-names>Jian-Ying</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2359123/overview"/>
</contrib>
</contrib-group>
<aff>
<institution>Department of Nursing Care</institution>, <institution>Shanghai Songjiang District Central Hospital</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2235861/overview">Chi Zhang</ext-link>, Nanyang Technological University, Singapore</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1415991/overview">Xiaojun Zhou</ext-link>, Donghua University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1905244/overview">Bing Guo</ext-link>, Harbin Institute of Technology, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1396369/overview">Xiuhui Wang</ext-link>, Shanghai University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Jian-Ying Zhou, <email>zjysj123456@163.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>11</volume>
<elocation-id>1248283</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>06</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>07</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Yao and Zhou.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Yao and Zhou</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Introduction:</bold> The effective treatment of glioblastoma still remains a great challenge. We herein report the development of chlorin e6 (Ce6)-conjugated iron oxide (Fe<sub>3</sub>O<sub>4</sub>-Ce6) nanoparticles for ablation of glioblastoma cells via combining photothermal therapy (PTT) with photodynamic therapy (PDT).</p>
<p>
<bold>Methods:</bold> Ce6 was conjugated to the synthesized Fe<sub>3</sub>O<sub>4</sub> nanoparticles to form Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles displaying the optical property of Ce6.</p>
<p>
<bold>Results and discussion:</bold> Under 808&#x00a0;nm laser irradiation, Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles generated heat and the temperature increase did not have obvious changes after five cycles of laser irradiation, suggesting their good photothermal effect and photothermal stability. In addition, 660&#x00a0;nm laser irradiation of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles produced singlet oxygen (<sup>1</sup>O<sub>2</sub>) to mediate PDT. The Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles without laser irradiation showed a low cytotoxicity, but they would obviously kill C6 cancer cells after laser irradiation via the combinational effect of PTT and PDT. Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles thus could be used as a nanotherapeutic agent for combinational ablation of glioblastoma cells.</p>
</abstract>
<kwd-group>
<kwd>glioblastoma</kwd>
<kwd>iron oxide nanoparticles</kwd>
<kwd>photothermal therapy</kwd>
<kwd>photodynamic therapy</kwd>
<kwd>cancer therapy</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Biomaterials</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>1 Introduction</title>
<p>Glioblastoma is the most common primary malignant tumor of the nervous system, accounting for about 40%&#x2013;50% of all primary intracranial tumors (<xref ref-type="bibr" rid="B34">van Landeghem et al., 2009</xref>; <xref ref-type="bibr" rid="B40">Xin et al., 2012</xref>; <xref ref-type="bibr" rid="B11">Fang et al., 2015</xref>; <xref ref-type="bibr" rid="B27">Pinel et al., 2019</xref>). Because of the high degree of malignancy and short overall survival of glioblastoma patients, it is still a great challenge for the treatment of glioblastoma (<xref ref-type="bibr" rid="B19">Kuang et al., 2018</xref>; <xref ref-type="bibr" rid="B6">Choi et al., 2020</xref>; <xref ref-type="bibr" rid="B15">Gregory et al., 2020</xref>; <xref ref-type="bibr" rid="B46">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="B36">Wang et al., 2023</xref>). At present, the treatment of glioma is mainly based on surgery, which can be used to resect early small tumors in appropriate locations (<xref ref-type="bibr" rid="B20">Lara-Velazquez et al., 2017</xref>; <xref ref-type="bibr" rid="B41">Zhang et al., 2019a</xref>; <xref ref-type="bibr" rid="B8">De Witt Hamer et al., 2019</xref>). As the tumor grows due to its unclear boundaries, it is difficult to completely remove tumor cells (<xref ref-type="bibr" rid="B38">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="B9">Dhar et al., 2022</xref>; <xref ref-type="bibr" rid="B32">Sandbhor et al., 2022</xref>; <xref ref-type="bibr" rid="B44">Zhang et al., 2023</xref>). Therefore, chemotherapy, radiotherapy, and immunotherapy have been used to combine surgery to further delay the progression of the disease and improve survival time (<xref ref-type="bibr" rid="B42">Zhang et al., 2019b</xref>; <xref ref-type="bibr" rid="B31">Ruan et al., 2019</xref>; <xref ref-type="bibr" rid="B16">Han et al., 2020</xref>; <xref ref-type="bibr" rid="B24">Lu et al., 2020</xref>; <xref ref-type="bibr" rid="B1">Alghamri et al., 2022</xref>; <xref ref-type="bibr" rid="B37">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="B23">Li et al., 2022</xref>; <xref ref-type="bibr" rid="B33">Sun et al., 2022</xref>; <xref ref-type="bibr" rid="B43">Zhang et al., 2022</xref>; <xref ref-type="bibr" rid="B44">Zhang et al., 2023</xref>). However, due to short-term recurrence and drug resistance, the treatment effects of glioblastoma is not satisfactory.</p>
<p>Phototherapy is a type treatment strategy that relies on the light irradiation of tumors (<xref ref-type="bibr" rid="B39">Xie et al., 2020</xref>; <xref ref-type="bibr" rid="B22">Li et al., 2021</xref>; <xref ref-type="bibr" rid="B47">Zheng et al., 2021</xref>; <xref ref-type="bibr" rid="B21">Lee et al., 2022</xref>; <xref ref-type="bibr" rid="B29">Roy et al., 2023a</xref>). Compared to traditional chemotherapy, phototherapy shows the advantages of high selectivity, low side effects and negligible drug resistance (<xref ref-type="bibr" rid="B2">Cao et al., 2021</xref>; <xref ref-type="bibr" rid="B18">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="B28">Pivetta et al., 2021</xref>; <xref ref-type="bibr" rid="B12">Feng et al., 2022</xref>). Photothermal therapy (PTT) utilizes the generated heat after laser irradiation of photothermal agents to ablate tumor cells (<xref ref-type="bibr" rid="B13">Fernandes et al., 2020</xref>; <xref ref-type="bibr" rid="B14">Gao et al., 2021</xref>; <xref ref-type="bibr" rid="B25">Lv et al., 2021</xref>; <xref ref-type="bibr" rid="B17">Huang et al., 2022</xref>). Photodynamic therapy (PDT) produces reactive oxygen species (ROS) to kill cancer cells via activating photosensitizers by light (<xref ref-type="bibr" rid="B3">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="B26">Pham et al., 2021</xref>; <xref ref-type="bibr" rid="B35">Wan et al., 2021</xref>; <xref ref-type="bibr" rid="B30">Roy et al., 2023b</xref>). Currently, both PTT and PDT have been widely explored for treatments of different tumors. In addition, the combinations of PTT and PDT can lead to better efficacy for suppressing tumors (<xref ref-type="bibr" rid="B7">Curcio et al., 2019</xref>; <xref ref-type="bibr" rid="B45">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="B5">Chen et al., 2021</xref>).</p>
<p>In this study, we reported the development of chlorin e6 (Ce6)-conjugated iron oxide (Fe<sub>3</sub>O<sub>4</sub>-Ce6) nanoparticles for ablation of glioblastoma cells by PTT-combined PDT. Fe<sub>3</sub>O<sub>4</sub> nanoparticles were first synthesized and their surface modification of Ce6 led to the formation of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles, in which, Fe<sub>3</sub>O<sub>4</sub> nanoparticles and Ce6 were used as photothermal agents and photosensitizers, respectively. The morphology, hydrodynamic size, zeta potential, absorbance and fluorescence properties of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles were studied. Under 808 and 660&#xa0;nm laser irradiation, Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles could mediate PTT and PDT by generating heat and ROS. In addition, they were found to have a good photothermal stability after five cycles of laser irradiation. Via combining PTT and PDT, Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles effectively killed C6 cells under 808 and 660&#xa0;nm laser irradiation. Thus, Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles could be used for ablation of glioblastoma cells via combinational therapy.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Materials</title>
<p>Ce6 was purchased from America J&#x26;K Scientific Ltd. (United States). Bovine serum albumin (BSA), N-(3-dimethylaminopropyl)-N-ethyl-carbodiimide hydrochloride crystalline (EDC), N-hydroxysuccin-imide (NHS), singlet oxygen sensor green (SOSG), 2&#x2032;,7&#x2032;-dichlorodihydrofluorescein diacetate (H<sub>2</sub>DCFDA) and calcein-AM/propidium iodide (PI) double staining kit were purchased from Sigma Aldrich (United States). FeCl<sub>3</sub>.6H<sub>2</sub>O and FeCl<sub>2</sub>.4H<sub>2</sub>O were obtained from Aladdin Biochemical Technology Co., Ltd. (Shanghai, China). CCK-8 was purchased from Dojindo Laboratories (Japan). All the other chemicals were purchased from National Pharmaceutical Corporation (Shanghai, China).</p>
</sec>
<sec id="s2-2">
<title>2.2 Characterization techniques</title>
<p>Transmission electron microscopy (TEM) images were obtained using Tecnai G2 20 TWIN TEM (FEI, United States). Hydrodynamic sizes and zeta potential values were measured using a Zetasizer (Nano S90, UK). UV-vis absorptions were measured using persee UV-vis spectrophotometer (TU-1810, China). Fluorescence spectra were recorded using fluorescence spectrophotometer (Shimadzu RF-6000, Japan).</p>
</sec>
<sec id="s2-3">
<title>2.3 Synthesis of Fe<sub>3</sub>O<sub>4</sub> nanoparticles</title>
<p>FeCl<sub>2</sub>.4H<sub>2</sub>O (89.0&#xa0;mg) and FeCl<sub>3</sub>.6H<sub>2</sub>O (157.0&#xa0;mg) were dissolved in 8.0&#xa0;mL water, and then 5&#xa0;mL aqueous solution containing NaOH (1.0&#xa0;g) and BSA (20.0&#xa0;mg) was dropped into above solution. The resulted solution was stirred at 80&#xb0;C for 30&#xa0;min and black products were formed. Then the solution was cooled to room temperature and the formed products were precipitated by using magnetic beads. After purification through water washing, BSA-coated Fe<sub>3</sub>O<sub>4</sub> nanoparticles were obtained.</p>
</sec>
<sec id="s2-4">
<title>2.4 Synthesis of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles</title>
<p>Ce6 (12.0&#xa0;mg), EDC (24.6&#xa0;mg) and NHS (23.0&#xa0;mg) were dissolved in 5&#xa0;mL dimethyl sulfoxide and the solution were stirred at room temperature for 3&#xa0;h. Then above solution was dropped into 5&#xa0;mL solution of BSA-coated Fe<sub>3</sub>O<sub>4</sub> nanoparticles, and the reaction was contained at room temperature for 24&#xa0;h. The products were collected using magnetic beads and then further washed with water. After that, Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles were obtained.</p>
</sec>
<sec id="s2-5">
<title>2.5 Evaluation of photodynamic efficacy</title>
<p>The solution of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles were mixed with SOSG, and the resulted solutions were irradiated by 660&#xa0;nm laser (0.3&#xa0;W/cm<sup>2</sup>) for different times. The fluorescence spectra of solutions without or with laser irradiation were recorded. The fluorescence intensities of solutions at 525&#xa0;nm were used to evaluate the <sup>1</sup>O<sub>2</sub> generation by calculating the fluorescence enhancement (F/F<sub>0</sub>).</p>
</sec>
<sec id="s2-6">
<title>2.6 Evaluation of photothermal efficacy</title>
<p>The solutions of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles at different concentrations were irradiated by 808&#xa0;nm laser (1.0&#xa0;W/cm<sup>2</sup>), and the temperatures of solutions under laser irradiation were measured. To evaluate the photothermal stability, the nanoparticle solutions were irradiated by 808&#xa0;nm laser (1.0&#xa0;W/cm<sup>2</sup>) for five times and the temperatures of solutions were measured.</p>
</sec>
<sec id="s2-7">
<title>2.7 Evaluation of cell viability</title>
<p>The cell lines (brain endothelial bEnd.3 cells and rat C6 glioma cells) presents in this study were obtained from American Type Culture Collection (ATCC, United States). The bEnd.3 and C6 cancer cells were incubated with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles at different concentrations for 24 h, and then the cells were washed with PBS. The cells were then incubated in cell culture medium containing CCK-8 agent for 2&#xa0;h. The supernatant of treated cells was collected to measure the absorbance at 450&#xa0;nm using a Thermo Scientific Multiskan MK3 ELISA reader (Thermo scientific, United States), and then the cell viabilities were calculated.</p>
</sec>
<sec id="s2-8">
<title>2.8 Evaluation of therapeutic efficacy</title>
<p>C6 cancer cells were incubated with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles for 24&#xa0;h and then the cells were irradiated by 808&#xa0;nm laser (1.0&#xa0;W/cm<sup>2</sup>) for 5 min and 660&#xa0;nm laser (0.3&#xa0;W/cm<sup>2</sup>) for 5&#xa0;min. The cells were further incubated for 6&#xa0;h and then the cell viabilities of cells were measured using CCK-8 analysis.</p>
</sec>
<sec id="s2-9">
<title>2.9 Calcein-AM/PI double staining</title>
<p>C6 cancer cells were incubated with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles for 24&#xa0;h and then the cells were cultured in cell culture medium containing calcein-AM/PI double staining agent. The 808&#xa0;nm laser (1.0&#xa0;W/cm<sup>2</sup>, 5&#xa0;min) and 660&#xa0;nm laser (0.3&#xa0;W/cm<sup>2</sup>, 5&#xa0;min) was used to treat the cells. The fluorescence images of cells in various treatment groups were captured using a fluorescence microscope.</p>
</sec>
<sec id="s2-10">
<title>2.10 Intracellular ROS generation evaluation</title>
<p>C6 cancer cells were incubated with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles for 24&#xa0;h and then the cells were further cultured in cell culture medium containing H<sub>2</sub>DCFDA for 30&#xa0;min. The cells were then irradiated by 660&#xa0;nm laser (1.0&#xa0;W/cm<sup>2</sup>) for 5&#xa0;min. Fluorescence images of cells in various treatment groups were captured using a fluorescence microscope.</p>
</sec>
<sec id="s2-11">
<title>2.11 Cellular uptake evaluation</title>
<p>C6 cancer cells were incubated with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles at different concentration for 12 h, and then the cells were washed with PBS to remove free nanoparticles. The contents of nanoparticles inside cells were evaluated by measuring intracellular Fe concentration using inductively coupled plasma optical emission spectroscopy (ICP-OES).</p>
</sec>
<sec id="s2-12">
<title>2.12 Statistical analysis</title>
<p>The data were provided as mean &#xb1; standard deviation (SD). Statistical analysis was carried out using one-way ANOVA statistical analysis. Statistical significance was indicated as (&#x2a;) <italic>p</italic> &#x3c; 0.05, (&#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.01, and (&#x2a;&#x2a;&#x2a;) <italic>p</italic> &#x3c; 0.001.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>3 Results and discussion</title>
<sec id="s3-1">
<title>3.1 Characterization of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles</title>
<p>TEM image showed that the formed Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles had a spherical morphology and their size distribution was homogeneous (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The hydrodynamic size and zeta potential of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles was measured to be 80.0&#xa0;nm and &#x2212;15.4 mV, respectively (<xref ref-type="fig" rid="F1">Figure 1B</xref>). As shown in UV-vis spectra, the characteristic peaks of Ce6 at 400&#xa0;nm and 641&#xa0;nm could be detected in the absorbance spectrum of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles (<xref ref-type="fig" rid="F1">Figure 1C</xref>), which however could not be detected in absorbance spectrum of Fe<sub>3</sub>O<sub>4</sub> nanoparticles, confirming the conjugation of Ce6 to Fe<sub>3</sub>O<sub>4</sub> nanoparticles. In addition, Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles showed a fluorescence emission at around 670&#xa0;nm (<xref ref-type="fig" rid="F1">Figure 1D</xref>), and the fluorescence signal was also observed for Ce6. However, Fe<sub>3</sub>O<sub>4</sub> nanoparticles did not have fluorescence property. These results suggested that Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles showed the optical properties of Ce6.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Characterization of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. <bold>(A)</bold> TEM image of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. <bold>(B)</bold> Hydrodynamic size of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. <bold>(C)</bold> UV-Vis absorbance spectra of Fe<sub>3</sub>O<sub>4</sub> nanoparticles, Ce6 and Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. <bold>(D)</bold> Fluorescence spectra of Fe<sub>3</sub>O<sub>4</sub> nanoparticles, Ce6 and Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles.</p>
</caption>
<graphic xlink:href="fbioe-11-1248283-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>3.2 Photothermal property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles</title>
<p>The photothermal property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles under 808&#xa0;nm laser irradiation was evaluated. Under laser irradiation, the temperature of solutions containing Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles gradually increased, which reached around 58.8&#xb0;C after 6&#xa0;min of laser irradiation (<xref ref-type="fig" rid="F2">Figure 2A</xref>). This result verified the good photothermal property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. The temperature increase for Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles was found to be concentration-dependent, as higher concentration led to a higher temperature (<xref ref-type="fig" rid="F2">Figure 2B</xref>). At the concentration of 500&#xa0;&#x3bc;g/mL, the temperature increased to 58.8&#xb0;C after 6&#xa0;min of laser irradiation. In addition, the temperature increase did not have obvious changes after 5 cycles of laser on and laser off (<xref ref-type="fig" rid="F2">Figure 2C</xref>). These results verified the good photothermal stability of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. The good photothermal effect and good photothermal stability were similarly observed for Fe<sub>3</sub>O<sub>4</sub> nanoparticles as reported in a previous study (<xref ref-type="bibr" rid="B4">Chen et al., 2023</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Photothermal property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. <bold>(A)</bold> Temperature changes of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles under 808&#xa0;nm laser irradiation for laser on (6&#xa0;min) and laser off (6&#xa0;min). <bold>(B)</bold> Temperature increase for Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles at different concentrations under 808&#xa0;nm laser irradiation. <bold>(C)</bold> Temperature changes of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles after five cycles of laser on and laser off.</p>
</caption>
<graphic xlink:href="fbioe-11-1248283-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 Photodynamic property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles</title>
<p>The photodynamic property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles was evaluated by measuring the generation of <sup>1</sup>O<sub>2</sub> under 660&#xa0;nm laser irradiation using SOSG as the <sup>1</sup>O<sub>2</sub> probe. The fluorescence intensity of SOSG for solutions containing Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles gradually increased under 660&#xa0;nm laser irradiation (<xref ref-type="fig" rid="F3">Figure 3A</xref>). This should be because the generated <sup>1</sup>O<sub>2</sub> turned on the fluorescence signals of SOSG. The fluorescence intensity of SOSG for solutions containing Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles increased by 1.2-, 1.4-, 1.6-, 1.7-, 1.9-, 2.1-, 2.2-, 2.3-, 2.5-, and 2.6-fold after 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10&#xa0;min of laser irradiation (<xref ref-type="fig" rid="F3">Figure 3B</xref>). These results confirmed the generation of <sup>1</sup>O<sub>2</sub> via photodynamic effect for Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles under 660&#xa0;nm laser irradiation. The <sup>1</sup>O<sub>2</sub> generating efficacy of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles was higher than that of protoporphyrin IX (PpIX)-modified Fe<sub>3</sub>O<sub>4</sub> nanoparticles (<xref ref-type="bibr" rid="B10">Ding et al., 2022</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Photodynamic property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. <bold>(A)</bold> Fluorescence spectra of SOSG in solutions containing Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles under 660&#xa0;nm laser irradiation for different time. <bold>(B)</bold> Fluorescence changes of SOSG in solutions containing Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles under 660&#xa0;nm laser irradiation for different time.</p>
</caption>
<graphic xlink:href="fbioe-11-1248283-g003.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>3.4 Cell viability and therapeutic efficacy evaluation</title>
<p>To evaluate the cytotoxicity of nanoparticles to normal cells, bEnd.3 cells were incubated with these nanoparticles. After 24&#xa0;h of incubation, the cell viability did not have obvious decline (<xref ref-type="fig" rid="F4">Figure 4A</xref>). C6 cancer cells were incubated with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles at different concentrations for 24 h, and the CCK-8 analysis showed that the cell viability of these treated cells was still higher than 85.0% (<xref ref-type="fig" rid="F4">Figure 4B</xref>), which suggested the low cytotoxicity for Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles. To evaluate the <italic>in vitro</italic> therapeutic efficacy, C6 cells were incubated with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles and then treated by 808 and 660&#xa0;nm laser. The cell viability for PBS &#x2b; laser and Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle-treated groups was similar to that in PBS control group (<xref ref-type="fig" rid="F4">Figure 4C</xref>). These results suggested that laser irradiation and sole Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle treatment did not have obvious therapeutic effect. In contrast, the cell viability of C6 cells in Fe<sub>3</sub>O<sub>4</sub>-Ce6 &#x2b; laser group was only 19.6%, which suggested the good cell killing effect for Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles plus laser irradiation via the combinational effect of PTT and PDT. The therapeutic efficacy of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles via PTT-combined PDT was higher than that of Fe<sub>3</sub>O<sub>4</sub> nanoparticles via a sole PTT effect (<xref ref-type="bibr" rid="B4">Chen et al., 2023</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Cell viability and therapeutic efficacy evaluation. <bold>(A)</bold> Cell viability of bEnd.3 cells after incubation with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles at different concentrations for 24&#xa0;h <bold>(B)</bold> Cell viability of C6 cells after incubation with Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles at different concentrations for 24&#xa0;h <bold>(C)</bold> Cell viability of C6 cells in PBS, PBS plus laser irradiation, Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle treatment, and Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle treatment plus laser irradiation groups.</p>
</caption>
<graphic xlink:href="fbioe-11-1248283-g004.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>3.5 Dead/living staining analysis</title>
<p>Dead/living staining was then used to evaluate the therapeutic efficacy. As shown in the fluorescence images, only green fluorescence signals (living cells) were observed for cells in PBS &#x2b; laser and Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle-treated groups, which was similar to those in PBS control group (<xref ref-type="fig" rid="F5">Figure 5A</xref>). In contrast, both green and red fluorescence signals could be detected for cells in Fe<sub>3</sub>O<sub>4</sub>-Ce6 &#x2b; laser group. The red fluorescence signals in this group indicated the death of cancer cells after treatment. Quantitative analysis showed that the percentage of dead cells and living cells in Fe<sub>3</sub>O<sub>4</sub>-Ce6 &#x2b; laser group was 83.6% and 16.4%, respectively (<xref ref-type="fig" rid="F5">Figure 5B</xref>). The percentages of living cells in PBS, PBS &#x2b; laser and Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle-treated groups were around 99.0%. These results further confirmed the good therapeutic efficacy for Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles plus laser irradiation.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Dead/living staining analysis. <bold>(A)</bold> Dead and living fluorescence staining images of C6 cells after different treatments. <bold>(B)</bold> Quantitative analysis of the percentages of dead and living cells in different groups.</p>
</caption>
<graphic xlink:href="fbioe-11-1248283-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>3.6 Intracellular ROS generation evaluation</title>
<p>To confirm the photodynamic effect, the generation of ROS inside cells after treatments was evaluated using H<sub>2</sub>DCFHDA as the ROS probe. Obvious green fluorescence signals could be detected in Fe<sub>3</sub>O<sub>4</sub>-Ce6 &#x2b; laser group (<xref ref-type="fig" rid="F6">Figure 6A</xref>), which verified the generation of ROS in this group. However, nearly no green fluorescence signals were observed in PBS and PBS &#x2b; laser group. The very weak green fluorescence signal in Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle-treated group may be due to the generation of a little ROS via Fenton reaction. The fluorescence intensity of green signals in Fe<sub>3</sub>O<sub>4</sub>-Ce6 &#x2b; laser group was at least 82.0-fold higher than that in the other groups (<xref ref-type="fig" rid="F6">Figure 6B</xref>). These results confirmed the generation of ROS inside cancer cells via photodynamic effect after Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle treatment plus 660&#xa0;nm laser irradiation.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Intracellular ROS generation evaluation. <bold>(A)</bold> Fluorescence images of Ce6 cells in different groups to show the generation of ROS inside cells. <bold>(B)</bold> Quantitative fluorescence intensity of ROS in different groups.</p>
</caption>
<graphic xlink:href="fbioe-11-1248283-g006.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>3.7 Cellular uptake evaluation</title>
<p>The cellular uptake of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles by C6 cancer cells were investigated. The results showed that the intracellular Fe levels in the treated cells gradually increased in a concentration depend manner (<xref ref-type="fig" rid="F7">Figure 7</xref>). A higher concentration of nanoparticles led to a higher intracellular Fe level. These results confirmed the effective cellular uptake of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles by C6 cancer cells.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Cellular uptake analysis of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles by C6 cancer cells.</p>
</caption>
<graphic xlink:href="fbioe-11-1248283-g007.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>4 Conclusion</title>
<p>We have developed a nanoparticle system containing Ce6 and Fe<sub>3</sub>O<sub>4</sub> nanoparticles for <italic>in vitro</italic> ablation of glioblastoma cells via combining PTT with PDT. Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles were synthesized through conjugating Ce6 to Fe<sub>3</sub>O<sub>4</sub> nanoparticles that showed negative surface potential and the optical property of Ce6. Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles could mediate PTT and PDT via producing heat and ROS under 808 and 660&#xa0;nm laser irradiation. The treatment of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles plus laser irradiation obviously killed cancer cells and reduced the cell viability, which were verified using CCK-8 analysis and living/dead staining. Fluorescence imaging confirmed the generation of ROS inside cancer cells for Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticle treatment plus laser irradiation. In view of the good fluorescence property of Fe<sub>3</sub>O<sub>4</sub>-Ce6 nanoparticles, they may be used for fluorescence imaging-guided combination therapy of cancer.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Author contributions</title>
<p>J-YZ: Corresponding authors, conception, design of the study and revising the manuscript; HY: acquisition, analysis, interpretation of the data, and drafting the article. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This study was supported by the Fundamental Research Funds in Shanghai Songjiang District Central Hospital.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alghamri</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mujeeb</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Mauser</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taher</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thalla</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Systemic delivery of an adjuvant CXCR4&#x2013;CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy</article-title>. <source>ACS Nano</source> <volume>16</volume>, <fpage>8729</fpage>&#x2013;<lpage>8750</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.1c07492</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Martino</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Pijpers</surname>
<given-names>I. A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Photoactivated nanomotors via aggregation induced emission for enhanced phototherapy</article-title>. <source>Nat. Commun.</source> <volume>12</volume>, <fpage>2077</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-22279-w</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Advances in nanomaterials for photodynamic therapy applications: Status and challenges</article-title>. <source>Biomaterials</source> <volume>237</volume>, <fpage>119827</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.119827</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Tumor acidic microenvironment-responsive promodulator iron oxide nanoparticles for photothermal-enhanced chemodynamic immunotherapy of cancer</article-title>. <source>ACS Biomater. Sci. Eng.</source> <volume>9</volume>, <fpage>773</fpage>&#x2013;<lpage>783</lpage>. <pub-id pub-id-type="doi">10.1021/acsbiomaterials.2c01287</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>An injectable hydrogel for simultaneous photothermal therapy and photodynamic therapy with ultrahigh efficiency based on carbon dots and modified cellulose nanocrystals</article-title>. <source>Adv. Funct. Mat.</source> <volume>31</volume>, <fpage>2106079</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.202106079</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Im</surname>
<given-names>H.-J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme</article-title>. <source>J. Nanobiotechnol.</source> <volume>18</volume>, <fpage>122</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-020-00684-5</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curcio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Cabana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Espinosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baptiste</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Menguy</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Iron oxide nanoflowers@ CuS hybrids for cancer tri-therapy: Interplay of photothermal therapy, magnetic hyperthermia and photodynamic therapy</article-title>. <source>Theranostics</source> <volume>9</volume>, <fpage>1288</fpage>&#x2013;<lpage>1302</lpage>. <pub-id pub-id-type="doi">10.7150/thno.30238</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Witt Hamer</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>V. K.</given-names>
</name>
<name>
<surname>Zwinderman</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Ackermans</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ardon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Boomstra</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery</article-title>. <source>J. Neuro-Oncol.</source> <volume>144</volume>, <fpage>313</fpage>&#x2013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-019-03229-5</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>A review of recent advances in magnetic nanoparticle-based theranostics of glioblastoma</article-title>. <source>Nanomedicine</source> <volume>17</volume>, <fpage>107</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2021-0348</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy</article-title>. <source>Acta Biomater.</source> <volume>149</volume>, <fpage>334</fpage>&#x2013;<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2022.06.041</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Stephen</surname>
<given-names>Z. R.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Kievit</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>D. T.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Temozolomide nanoparticles for targeted glioblastoma therapy</article-title>. <source>ACS Appl. Mat. Interfaces</source> <volume>7</volume>, <fpage>6674</fpage>&#x2013;<lpage>6682</lpage>. <pub-id pub-id-type="doi">10.1021/am5092165</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Acceptor planarization and donor rotation: A facile strategy for realizing synergistic cancer phototherapy via type I PDT and PTT</article-title>. <source>ACS Nano</source> <volume>16</volume>, <fpage>4162</fpage>&#x2013;<lpage>4174</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.1c10019</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Correia</surname>
<given-names>I. J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Overview of the application of inorganic nanomaterials in cancer photothermal therapy</article-title>. <source>Biomater. Sci.</source> <volume>8</volume>, <fpage>2990</fpage>&#x2013;<lpage>3020</lpage>. <pub-id pub-id-type="doi">10.1039/d0bm00222d</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanoagent&#x2010;promoted mild&#x2010;temperature photothermal therapy for cancer treatment</article-title>. <source>Adv. Funct. Mat.</source> <volume>31</volume>, <fpage>2100738</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.202100738</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname>
<given-names>J. V.</given-names>
</name>
<name>
<surname>Kadiyala</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cadena</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Habeel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ruoslahti</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy</article-title>. <source>Nat. Commun.</source> <volume>11</volume>, <fpage>5687</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-19225-7</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Paclitaxel-loaded dextran nanoparticles decorated with RVG29 peptide for targeted chemotherapy of glioma: An <italic>in vivo</italic> study</article-title>. <source>New J. Chem.</source> <volume>44</volume>, <fpage>5692</fpage>&#x2013;<lpage>5701</lpage>. <pub-id pub-id-type="doi">10.1039/c9nj05366b</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ullah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Advances in image-guided drug delivery for antibacterial therapy</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>192</volume>, <fpage>114634</fpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2022.114634</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Nanoscale metal-organic frameworks for tumor phototherapy</article-title>. <source>J. Mat. Chem. B</source> <volume>9</volume>, <fpage>3756</fpage>&#x2013;<lpage>3777</lpage>. <pub-id pub-id-type="doi">10.1039/d1tb00349f</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. P.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>iRGD modified chemo&#x2010;immunotherapeutic nanoparticles for enhanced immunotherapy against glioblastoma</article-title>. <source>Adv. Funct. Mat.</source> <volume>28</volume>, <fpage>1800025</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.201800025</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lara-Velazquez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Al-Kharboosh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jeanneret</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vazquez-Ramos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mahato</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tavanaiepour</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Advances in brain tumor surgery for glioblastoma in adults</article-title>. <source>Brain Sci.</source> <volume>7</volume>, <fpage>166</fpage>. <pub-id pub-id-type="doi">10.3390/brainsci7120166</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Y.-S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T.-I.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Materials and device design for advanced phototherapy systems</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>186</volume>, <fpage>114339</fpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2022.114339</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Recent advances and prospects of carbon dots in phototherapy</article-title>. <source>Chem. Eng. J.</source> <volume>408</volume>, <fpage>127245</fpage>. <pub-id pub-id-type="doi">10.1016/j.cej.2020.127245</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Radiotherapy for glioblastoma: Clinical issues and nanotechnology strategies</article-title>. <source>Biomater. Sci.</source> <volume>10</volume>, <fpage>892</fpage>&#x2013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1039/d1bm01401c</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Jue</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Mcdonald</surname>
<given-names>K. L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: An <italic>in vitro</italic> rationale for translational studies</article-title>. <source>Sci. Rep.</source> <volume>10</volume>, <fpage>18156</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-75372-3</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Noble metal nanomaterials for NIR&#x2010;triggered photothermal therapy in cancer</article-title>. <source>Adv. Healthc. Mat.</source> <volume>10</volume>, <fpage>2001806</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202001806</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pham</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>V.-N.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy</article-title>. <source>Chem. Rev.</source> <volume>121</volume>, <fpage>13454</fpage>&#x2013;<lpage>13619</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.1c00381</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boura</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Barberi-Heyob</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>138</volume>, <fpage>344</fpage>&#x2013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2018.10.013</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pivetta</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Botteon</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Marcato</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Raposo</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanoparticle systems for cancer phototherapy: An overview</article-title>. <source>Nanomaterials</source> <volume>11</volume>, <fpage>3132</fpage>. <pub-id pub-id-type="doi">10.3390/nano11113132</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bag</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bardhan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2023a</year>). <article-title>Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>197</volume>, <fpage>114821</fpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2023.114821</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2023b</year>). <article-title>Recent advances in nanoparticle-mediated antibacterial applications</article-title>. <source>Coord. Chem. Rev.</source> <volume>482</volume>, <fpage>215075</fpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2023.215075</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment</article-title>. <source>Nano Lett.</source> <volume>19</volume>, <fpage>8318</fpage>&#x2013;<lpage>8332</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.9b03968</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandbhor</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Goda</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Mohanty</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chaudhari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dutt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy</article-title>. <source>Nanoscale</source> <volume>14</volume>, <fpage>12773</fpage>&#x2013;<lpage>12788</lpage>. <pub-id pub-id-type="doi">10.1039/d2nr00171c</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy</article-title>. <source>Nat. Commun.</source> <volume>13</volume>, <fpage>5127</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-32837-5</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Landeghem</surname>
<given-names>F. K.</given-names>
</name>
<name>
<surname>Maier-Hauff</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>K.-T.</given-names>
</name>
<name>
<surname>Gneveckow</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles</article-title>. <source>Biomaterials</source> <volume>30</volume>, <fpage>52</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.09.044</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Conquering the hypoxia limitation for photodynamic therapy</article-title>. <source>Adv. Mat.</source> <volume>33</volume>, <fpage>2103978</fpage>. <pub-id pub-id-type="doi">10.1002/adma.202103978</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy</article-title>. <source>Nanoscale</source> <volume>15</volume>, <fpage>10904</fpage>&#x2013;<lpage>10938</lpage>. <pub-id pub-id-type="doi">10.1039/d3nr01667f</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>
<italic>In situ</italic> targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma</article-title>. <source>J. Control. Release</source> <volume>345</volume>, <fpage>786</fpage>&#x2013;<lpage>797</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.050</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Brain tumor cell membrane&#x2010;coated lanthanide&#x2010;doped nanoparticles for NIR&#x2010;IIb luminescence imaging and surgical navigation of glioma</article-title>. <source>Adv. Healthc. Mat.</source> <volume>11</volume>, <fpage>2200521</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202200521</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Duo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Emerging combination strategies with phototherapy in cancer nanomedicine</article-title>. <source>Chem. Soc. Rev.</source> <volume>49</volume>, <fpage>8065</fpage>&#x2013;<lpage>8087</lpage>. <pub-id pub-id-type="doi">10.1039/d0cs00215a</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sha</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles</article-title>. <source>Biomaterials</source> <volume>33</volume>, <fpage>8167</fpage>&#x2013;<lpage>8176</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.07.046</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2019a</year>). <article-title>Glioblastoma treatment modalities besides surgery</article-title>. <source>J. Cancer</source> <volume>10</volume>, <fpage>4793</fpage>&#x2013;<lpage>4806</lpage>. <pub-id pub-id-type="doi">10.7150/jca.32475</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>Second near-infrared photodynamic therapy and chemotherapy of orthotopic malignant glioblastoma with ultra-small Cu<sub>2-x</sub>Se nanoparticles</article-title>. <source>Nanoscale</source> <volume>11</volume>, <fpage>7600</fpage>&#x2013;<lpage>7608</lpage>. <pub-id pub-id-type="doi">10.1039/c9nr01789e</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>190</volume>, <fpage>114536</fpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2022.114536</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rashidi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Silvers</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma</article-title>. <source>Nat. Commun.</source> <volume>14</volume>, <fpage>1610</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-023-37328-9</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Near-infrared triggered Ti3C2/g-C3N4 heterostructure for mitochondria-targeting multimode photodynamic therapy combined photothermal therapy</article-title>. <source>Nano Today</source> <volume>34</volume>, <fpage>100919</fpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2020.100919</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Versatile metal-phenolic network nanoparticles for multitargeted combination therapy and magnetic resonance tracing in glioblastoma</article-title>. <source>Biomaterials</source> <volume>278</volume>, <fpage>121163</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121163</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The recent progress on metal&#x2013;organic frameworks for phototherapy</article-title>. <source>Chem. Soc. Rev.</source> <volume>50</volume>, <fpage>5086</fpage>&#x2013;<lpage>5125</lpage>. <pub-id pub-id-type="doi">10.1039/d1cs00056j</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>